Transfusion of pathogen‐reduced platelet components without leukoreduction

BACKGROUND Leukoreduction (LR) of platelet concentrate (PC) has evolved as the standard to mitigate risks of alloimmunization, clinical refractoriness, acute transfusion reactions (ATRs), and cytomegalovirus infection, but does not prevent transfusion‐associated graft‐versus‐host disease (TA‐GVHD)....

Full description

Saved in:
Bibliographic Details
Published inTransfusion (Philadelphia, Pa.) Vol. 59; no. 6; pp. 1953 - 1961
Main Authors Sim, Joycelyn, Tsoi, Wai Chiu, Lee, Cheuk Kwong, Leung, Rock, Lam, Clarence C. K., Koontz, Claudia, Liu, Amy Yingjie, Huang, Norman, Benjamin, Richard J, Vermeij, Hans J., Stassinopoulos, Adonis, Corash, Laurence, Lie, Albert K. W.
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.06.2019
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract BACKGROUND Leukoreduction (LR) of platelet concentrate (PC) has evolved as the standard to mitigate risks of alloimmunization, clinical refractoriness, acute transfusion reactions (ATRs), and cytomegalovirus infection, but does not prevent transfusion‐associated graft‐versus‐host disease (TA‐GVHD). Amotosalen–ultraviolet A pathogen reduction (A‐PR) of PC reduces risk of transfusion‐transmitted infection and TA‐GVHD. In vitro data indicate that A‐PR effectively inactivates WBCs and infectious pathogens. STUDY DESIGN AND METHODS A sequential cohort study evaluated A‐PR without LR, gamma irradiation, and bacterial screening in hematopoietic stem cell transplant (HSCT) recipients. The first cohort received conventional PC (control) processed without LR, but with gamma irradiation and bacterial screening. The second cohort received A‐PR PC (test) processed without: LR, bacterial screening, or gamma irradiation. The primary efficacy outcome was the 1‐hour corrected count increment. The primary safety outcome was treatment‐emergent ATR. Secondary outcomes included clinical refractoriness, and 100‐day status for engraftment, TA‐GVHD, HSCT‐GVHD, infections, and mortality. RESULTS Mean corrected count increment (× 103) of 33 test PC recipients was similar (18.9 ± 8.8 vs. 16.6 ± 8.4; p = 0.296) to that of 31 control PC recipients. Test recipients had a reduced, but nonsignificant, incidence of ATR (test = 9.1%, Control = 19.4%; p = 0.296). The frequencies of clinical refractoriness (0 of 33 vs. 4 of 31 patients) and refractory transfusions (6.6% vs. 19.3%) were lower in the test cohort (p = 0.05 and 0.02), respectively. No patient in either cohort had TA‐GVHD. Day 100 engraftment, HSCT‐GVHD, mortality, and infectious disease complications were similar between cohorts. CONCLUSIONS This study indicated that A‐PR PC without LR, gamma irradiation, or bacterial screening is feasible for support of HSCT.
AbstractList Leukoreduction (LR) of platelet concentrate (PC) has evolved as the standard to mitigate risks of alloimmunization, clinical refractoriness, acute transfusion reactions (ATRs), and cytomegalovirus infection, but does not prevent transfusion-associated graft-versus-host disease (TA-GVHD). Amotosalen-ultraviolet A pathogen reduction (A-PR) of PC reduces risk of transfusion-transmitted infection and TA-GVHD. In vitro data indicate that A-PR effectively inactivates WBCs and infectious pathogens. A sequential cohort study evaluated A-PR without LR, gamma irradiation, and bacterial screening in hematopoietic stem cell transplant (HSCT) recipients. The first cohort received conventional PC (control) processed without LR, but with gamma irradiation and bacterial screening. The second cohort received A-PR PC (test) processed without: LR, bacterial screening, or gamma irradiation. The primary efficacy outcome was the 1-hour corrected count increment. The primary safety outcome was treatment-emergent ATR. Secondary outcomes included clinical refractoriness, and 100-day status for engraftment, TA-GVHD, HSCT-GVHD, infections, and mortality. Mean corrected count increment (× 10 ) of 33 test PC recipients was similar (18.9 ± 8.8 vs. 16.6 ± 8.4; p = 0.296) to that of 31 control PC recipients. Test recipients had a reduced, but nonsignificant, incidence of ATR (test = 9.1%, Control = 19.4%; p = 0.296). The frequencies of clinical refractoriness (0 of 33 vs. 4 of 31 patients) and refractory transfusions (6.6% vs. 19.3%) were lower in the test cohort (p = 0.05 and 0.02), respectively. No patient in either cohort had TA-GVHD. Day 100 engraftment, HSCT-GVHD, mortality, and infectious disease complications were similar between cohorts. This study indicated that A-PR PC without LR, gamma irradiation, or bacterial screening is feasible for support of HSCT.
BACKGROUNDLeukoreduction (LR) of platelet concentrate (PC) has evolved as the standard to mitigate risks of alloimmunization, clinical refractoriness, acute transfusion reactions (ATRs), and cytomegalovirus infection, but does not prevent transfusion-associated graft-versus-host disease (TA-GVHD). Amotosalen-ultraviolet A pathogen reduction (A-PR) of PC reduces risk of transfusion-transmitted infection and TA-GVHD. In vitro data indicate that A-PR effectively inactivates WBCs and infectious pathogens. STUDY DESIGN AND METHODSA sequential cohort study evaluated A-PR without LR, gamma irradiation, and bacterial screening in hematopoietic stem cell transplant (HSCT) recipients. The first cohort received conventional PC (control) processed without LR, but with gamma irradiation and bacterial screening. The second cohort received A-PR PC (test) processed without: LR, bacterial screening, or gamma irradiation. The primary efficacy outcome was the 1-hour corrected count increment. The primary safety outcome was treatment-emergent ATR. Secondary outcomes included clinical refractoriness, and 100-day status for engraftment, TA-GVHD, HSCT-GVHD, infections, and mortality. RESULTSMean corrected count increment (× 103 ) of 33 test PC recipients was similar (18.9 ± 8.8 vs. 16.6 ± 8.4; p = 0.296) to that of 31 control PC recipients. Test recipients had a reduced, but nonsignificant, incidence of ATR (test = 9.1%, Control = 19.4%; p = 0.296). The frequencies of clinical refractoriness (0 of 33 vs. 4 of 31 patients) and refractory transfusions (6.6% vs. 19.3%) were lower in the test cohort (p = 0.05 and 0.02), respectively. No patient in either cohort had TA-GVHD. Day 100 engraftment, HSCT-GVHD, mortality, and infectious disease complications were similar between cohorts. CONCLUSIONSThis study indicated that A-PR PC without LR, gamma irradiation, or bacterial screening is feasible for support of HSCT.
BACKGROUND Leukoreduction (LR) of platelet concentrate (PC) has evolved as the standard to mitigate risks of alloimmunization, clinical refractoriness, acute transfusion reactions (ATRs), and cytomegalovirus infection, but does not prevent transfusion‐associated graft‐versus‐host disease (TA‐GVHD). Amotosalen–ultraviolet A pathogen reduction (A‐PR) of PC reduces risk of transfusion‐transmitted infection and TA‐GVHD. In vitro data indicate that A‐PR effectively inactivates WBCs and infectious pathogens. STUDY DESIGN AND METHODS A sequential cohort study evaluated A‐PR without LR, gamma irradiation, and bacterial screening in hematopoietic stem cell transplant (HSCT) recipients. The first cohort received conventional PC (control) processed without LR, but with gamma irradiation and bacterial screening. The second cohort received A‐PR PC (test) processed without: LR, bacterial screening, or gamma irradiation. The primary efficacy outcome was the 1‐hour corrected count increment. The primary safety outcome was treatment‐emergent ATR. Secondary outcomes included clinical refractoriness, and 100‐day status for engraftment, TA‐GVHD, HSCT‐GVHD, infections, and mortality. RESULTS Mean corrected count increment (× 10 3 ) of 33 test PC recipients was similar (18.9 ± 8.8 vs. 16.6 ± 8.4; p = 0.296) to that of 31 control PC recipients. Test recipients had a reduced, but nonsignificant, incidence of ATR (test = 9.1%, Control = 19.4%; p = 0.296). The frequencies of clinical refractoriness (0 of 33 vs. 4 of 31 patients) and refractory transfusions (6.6% vs. 19.3%) were lower in the test cohort (p = 0.05 and 0.02), respectively. No patient in either cohort had TA‐GVHD. Day 100 engraftment, HSCT‐GVHD, mortality, and infectious disease complications were similar between cohorts. CONCLUSIONS This study indicated that A‐PR PC without LR, gamma irradiation, or bacterial screening is feasible for support of HSCT.
BACKGROUND Leukoreduction (LR) of platelet concentrate (PC) has evolved as the standard to mitigate risks of alloimmunization, clinical refractoriness, acute transfusion reactions (ATRs), and cytomegalovirus infection, but does not prevent transfusion‐associated graft‐versus‐host disease (TA‐GVHD). Amotosalen–ultraviolet A pathogen reduction (A‐PR) of PC reduces risk of transfusion‐transmitted infection and TA‐GVHD. In vitro data indicate that A‐PR effectively inactivates WBCs and infectious pathogens. STUDY DESIGN AND METHODS A sequential cohort study evaluated A‐PR without LR, gamma irradiation, and bacterial screening in hematopoietic stem cell transplant (HSCT) recipients. The first cohort received conventional PC (control) processed without LR, but with gamma irradiation and bacterial screening. The second cohort received A‐PR PC (test) processed without: LR, bacterial screening, or gamma irradiation. The primary efficacy outcome was the 1‐hour corrected count increment. The primary safety outcome was treatment‐emergent ATR. Secondary outcomes included clinical refractoriness, and 100‐day status for engraftment, TA‐GVHD, HSCT‐GVHD, infections, and mortality. RESULTS Mean corrected count increment (× 103) of 33 test PC recipients was similar (18.9 ± 8.8 vs. 16.6 ± 8.4; p = 0.296) to that of 31 control PC recipients. Test recipients had a reduced, but nonsignificant, incidence of ATR (test = 9.1%, Control = 19.4%; p = 0.296). The frequencies of clinical refractoriness (0 of 33 vs. 4 of 31 patients) and refractory transfusions (6.6% vs. 19.3%) were lower in the test cohort (p = 0.05 and 0.02), respectively. No patient in either cohort had TA‐GVHD. Day 100 engraftment, HSCT‐GVHD, mortality, and infectious disease complications were similar between cohorts. CONCLUSIONS This study indicated that A‐PR PC without LR, gamma irradiation, or bacterial screening is feasible for support of HSCT.
Author Stassinopoulos, Adonis
Leung, Rock
Benjamin, Richard J
Tsoi, Wai Chiu
Vermeij, Hans J.
Corash, Laurence
Lie, Albert K. W.
Lee, Cheuk Kwong
Liu, Amy Yingjie
Koontz, Claudia
Huang, Norman
Sim, Joycelyn
Lam, Clarence C. K.
AuthorAffiliation 3 Cerus Corporation Concord California
2 Hong Kong Red Cross Blood Transfusion Service Yau Ma Tei Hong Kong
1 Queen Mary Hospital and University of Hong Kong Pok Fu Lam Hong Kong
AuthorAffiliation_xml – name: 1 Queen Mary Hospital and University of Hong Kong Pok Fu Lam Hong Kong
– name: 3 Cerus Corporation Concord California
– name: 2 Hong Kong Red Cross Blood Transfusion Service Yau Ma Tei Hong Kong
Author_xml – sequence: 1
  givenname: Joycelyn
  surname: Sim
  fullname: Sim, Joycelyn
  organization: Queen Mary Hospital and University of Hong Kong
– sequence: 2
  givenname: Wai Chiu
  surname: Tsoi
  fullname: Tsoi, Wai Chiu
  organization: Hong Kong Red Cross Blood Transfusion Service
– sequence: 3
  givenname: Cheuk Kwong
  surname: Lee
  fullname: Lee, Cheuk Kwong
  organization: Hong Kong Red Cross Blood Transfusion Service
– sequence: 4
  givenname: Rock
  surname: Leung
  fullname: Leung, Rock
  organization: Queen Mary Hospital and University of Hong Kong
– sequence: 5
  givenname: Clarence C. K.
  surname: Lam
  fullname: Lam, Clarence C. K.
  organization: Queen Mary Hospital and University of Hong Kong
– sequence: 6
  givenname: Claudia
  surname: Koontz
  fullname: Koontz, Claudia
  organization: Cerus Corporation
– sequence: 7
  givenname: Amy Yingjie
  surname: Liu
  fullname: Liu, Amy Yingjie
  organization: Cerus Corporation
– sequence: 8
  givenname: Norman
  surname: Huang
  fullname: Huang, Norman
  organization: Cerus Corporation
– sequence: 9
  givenname: Richard J
  surname: Benjamin
  fullname: Benjamin, Richard J
  organization: Cerus Corporation
– sequence: 10
  givenname: Hans J.
  surname: Vermeij
  fullname: Vermeij, Hans J.
  organization: Cerus Corporation
– sequence: 11
  givenname: Adonis
  orcidid: 0000-0002-5132-2558
  surname: Stassinopoulos
  fullname: Stassinopoulos, Adonis
  organization: Cerus Corporation
– sequence: 12
  givenname: Laurence
  orcidid: 0000-0002-8615-9869
  surname: Corash
  fullname: Corash, Laurence
  email: lcorash@cerus.com
  organization: Cerus Corporation
– sequence: 13
  givenname: Albert K. W.
  surname: Lie
  fullname: Lie, Albert K. W.
  organization: Queen Mary Hospital and University of Hong Kong
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30919465$$D View this record in MEDLINE/PubMed
BookMark eNp1kctKLDEURYMo2j4G_oAUONFBaZ5lZSJIc31AgyDtOKSTEy2tTsqkSnF2P-F-4_0So62igpmcQRbr7GSvo2UfPCC0TfAByeewj-6ACFrJJTQigh2VVEqxjEYYc1ISwugaWk_pDmNMJSaraI1hSSSvxAhNplH75IbUBF8EV3S6vw034P___RfBDgZs0bW6hxb6woR5lxf7PhVPTcaGvmhhuA9vYJ8Fm2jF6TbB1vvcQNenf6bj83JyeXYxPpmUhnMmSwGUW1zJGa0rzoihltVUwMxJcLMjKmspbE24FWBchRmz2lpbVVaC0dyRmm2g44W3G2ZzsCZHirpVXWzmOj6roBv1_cY3t-omPKqqFhiLV8HeuyCGhwFSr-ZNMtC22kMYkqJE5g_KoMjo7g_0LgzR5-cpShmnkteMZWp_QZkYUorgPsMQrF47Urkj9dZRZne-pv8kP0rJwOECeGpaeP7dpKZXpwvlC3_7oFQ
CitedBy_id crossref_primary_10_1016_j_transci_2022_103404
crossref_primary_10_1111_bjh_16093
crossref_primary_10_1111_trf_15807
crossref_primary_10_1182_hematology_2022000379
crossref_primary_10_1016_j_tmrv_2023_01_001
crossref_primary_10_1016_j_tracli_2022_08_147
crossref_primary_10_1111_trf_16312
crossref_primary_10_3390_pathogens10111499
crossref_primary_10_1016_j_cll_2020_10_005
crossref_primary_10_1111_trf_16768
Cites_doi 10.1111/trf.12371
10.1182/blood.V78.1.246.246
10.1111/trf.13478
10.1046/j.1537-2995.1999.39399219279.x
10.1111/trf.14589
10.1111/j.1537-2995.2010.02873.x
10.1056/NEJMoa0904084
10.1056/NEJM199712253372602
10.1111/j.1537-2995.2012.03566.x
10.1111/trf.12713
10.1111/j.1365-2141.2008.07189.x
10.1182/blood-2003-03-0940
10.1182/blood-2002-10-3143
10.1046/j.1423-0410.1999.7710001.x
10.1046/j.1537-2995.1998.38998409004.x
10.1111/trf.13171
10.1038/sj.bmt.1704284
10.1056/NEJM199712253372601
10.1016/S0140-6736(07)61198-2
10.1182/blood-2015-07-655944
10.1182/blood-2002-03-0932
10.1182/blood-2015-01-620872
10.1111/j.1537-2995.2009.02486.x
10.1111/trf.13673
10.1046/j.1537-2995.2000.40070761.x
10.4103/0973-6247.59384
10.1016/S0037-1963(01)90121-0
10.1111/j.1365-2141.2011.08635.x
10.1182/blood-2003-12-4443
10.1111/vox.12489
10.1046/j.1537-2995.2002.00094.x
10.1056/NEJMoa1212772
10.1111/vox.12410
10.1182/blood.V83.6.1683.1683
10.1111/j.1537-2995.2005.00639.x
10.1111/vox.12456
10.1111/j.1537-2995.2004.03351.x
10.1111/j.1537-2995.2007.01420.x
10.1111/j.1537-2995.2009.02151.x
10.1111/vox.12287
10.1182/blood.V86.9.3598.bloodjournal8693598
10.4049/jimmunol.171.11.6023
10.1111/trf.13530
ContentType Journal Article
Copyright 2019 The Authors. published by Wiley Periodicals, Inc. on behalf of AABB.
2019 The Authors. Transfusion published by Wiley Periodicals, Inc. on behalf of AABB.
2019 AABB
Copyright_xml – notice: 2019 The Authors. published by Wiley Periodicals, Inc. on behalf of AABB.
– notice: 2019 The Authors. Transfusion published by Wiley Periodicals, Inc. on behalf of AABB.
– notice: 2019 AABB
DBID 24P
WIN
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QO
7U9
8FD
FR3
H94
K9.
P64
7X8
5PM
DOI 10.1111/trf.15269
DatabaseName Wiley Online Library
Wiley Online Library Free Content
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Biotechnology Research Abstracts
Virology and AIDS Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Virology and AIDS Abstracts
Biotechnology Research Abstracts
Technology Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
CrossRef

Virology and AIDS Abstracts
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate REPLACEMENT OF LEUKOREDUCTION
EISSN 1537-2995
EndPage 1961
ExternalDocumentID 10_1111_trf_15269
30919465
TRF15269
Genre article
Journal Article
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
123
1OB
1OC
24P
29Q
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5HH
5LA
5RE
5VS
66C
6PF
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AAQQT
AASGY
AAWTL
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABLJU
ABPVW
ABQWH
ABXGK
ACAHQ
ACBNA
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHMBA
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EGARE
EJD
EMOBN
ESX
EX3
F00
F5P
FUBAC
G-S
G.N
GODZA
H.X
HF~
HGLYW
HZI
HZ~
H~9
IHE
IX1
J0M
J5H
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SJN
SUPJJ
TEORI
TWZ
UB1
UCJ
V8K
V9Y
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WQJ
WUP
WVDHM
WXI
WXSBR
X7M
XG1
YFH
YQI
YQJ
YUY
ZGI
ZXP
ZZTAW
~IA
~WT
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QO
7U9
8FD
FR3
H94
K9.
P64
7X8
5PM
ID FETCH-LOGICAL-c4439-5e24d069b286431c2d3825ebf9efb729895d814d5ecf6033daddd66d9eca4f183
IEDL.DBID 24P
ISSN 0041-1132
IngestDate Tue Sep 17 21:10:59 EDT 2024
Sat Aug 17 00:16:25 EDT 2024
Thu Oct 10 22:11:46 EDT 2024
Fri Aug 23 01:48:15 EDT 2024
Tue Aug 27 13:45:45 EDT 2024
Sat Aug 24 01:14:44 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
License Attribution-NonCommercial-NoDerivs
2019 The Authors. Transfusion published by Wiley Periodicals, Inc. on behalf of AABB.
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4439-5e24d069b286431c2d3825ebf9efb729895d814d5ecf6033daddd66d9eca4f183
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-5132-2558
0000-0002-8615-9869
OpenAccessLink https://onlinelibrary.wiley.com/doi/abs/10.1111%2Ftrf.15269
PMID 30919465
PQID 2234294833
PQPubID 1096380
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6850058
proquest_miscellaneous_2199195835
proquest_journals_2234294833
crossref_primary_10_1111_trf_15269
pubmed_primary_30919465
wiley_primary_10_1111_trf_15269_TRF15269
PublicationCentury 2000
PublicationDate June 2019
PublicationDateYYYYMMDD 2019-06-01
PublicationDate_xml – month: 06
  year: 2019
  text: June 2019
PublicationDecade 2010
PublicationPlace Hoboken, USA
PublicationPlace_xml – name: Hoboken, USA
– name: United States
– name: Bethesda
PublicationTitle Transfusion (Philadelphia, Pa.)
PublicationTitleAlternate Transfusion
PublicationYear 2019
Publisher John Wiley & Sons, Inc
Wiley Subscription Services, Inc
Publisher_xml – name: John Wiley & Sons, Inc
– name: Wiley Subscription Services, Inc
References 2004; 44
1997; 337
2004; 104
2004; 103
2015; 126
1991; 79
2013; 368
2015; 55
2003; 171
2010; 362
2016; 127
2015; 109
2017; 112
1994; 83
2008; 142
2009; 49
2005; 45
2012; 52
2016; 56
2011; 153
1998; 38
1995; 86
2004; 33
2007; 370
2000
2002; 42
1997; 37
1999; 39
2013; 53
2011; 51
2000; 40
2016; 112
1999; 77
2016; 111
2016
2015
2001; 38
2010; 4
2003; 101
2007; 47
2010; 50
2014; 54
2018; 58
e_1_2_8_28_1
e_1_2_8_24_1
e_1_2_8_47_1
e_1_2_8_26_1
e_1_2_8_49_1
Amsler L (e_1_2_8_44_1) 2016
Bowden RA (e_1_2_8_5_1) 1991; 79
e_1_2_8_3_1
e_1_2_8_9_1
e_1_2_8_43_1
e_1_2_8_22_1
e_1_2_8_45_1
e_1_2_8_17_1
e_1_2_8_19_1
e_1_2_8_13_1
e_1_2_8_36_1
e_1_2_8_15_1
e_1_2_8_38_1
Fiebig E (e_1_2_8_25_1) 1997; 37
e_1_2_8_32_1
e_1_2_8_11_1
e_1_2_8_34_1
e_1_2_8_30_1
e_1_2_8_29_1
e_1_2_8_46_1
e_1_2_8_27_1
e_1_2_8_48_1
Snyder E (e_1_2_8_7_1) 2000
e_1_2_8_2_1
e_1_2_8_4_1
e_1_2_8_6_1
e_1_2_8_8_1
e_1_2_8_21_1
e_1_2_8_42_1
e_1_2_8_23_1
e_1_2_8_40_1
e_1_2_8_18_1
e_1_2_8_39_1
e_1_2_8_14_1
e_1_2_8_35_1
e_1_2_8_16_1
e_1_2_8_37_1
Pelszynski MM (e_1_2_8_41_1) 1994; 83
Cerus Corporation (e_1_2_8_20_1) 2015
e_1_2_8_10_1
e_1_2_8_31_1
e_1_2_8_12_1
e_1_2_8_33_1
e_1_2_8_50_1
References_xml – volume: 56
  start-page: 1669
  year: 2016
  end-page: 72
  article-title: Assuring blood safety and availability: Zika virus, the latest emerging infectious disease battlefront
  publication-title: Transfusion
– volume: 126
  start-page: 406
  year: 2015
  end-page: 14
  article-title: A systematic review of transfusion‐associated graft‐versus‐host disease
  publication-title: Blood
– volume: 38
  start-page: 27
  issue: 4 Suppl 11
  year: 2001
  end-page: 33
  article-title: Inactivation of cytomegalovirus in platelet concentrates using Helinx™ technology
  publication-title: Semin Hematol
– volume: 49
  start-page: 1412
  year: 2009
  end-page: 22
  article-title: Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use
  publication-title: Transfusion
– volume: 39
  start-page: 239
  year: 1999
  end-page: 48
  article-title: Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light
  publication-title: Transfusion
– volume: 56
  start-page: 1569
  year: 2016
  end-page: 80
  article-title: Reducing the risk of transfusion‐transmitted cytomegalovirus infection: a systematic review and meta‐analysis
  publication-title: Transfusion
– volume: 109
  start-page: 342
  year: 2015
  end-page: 52
  article-title: A prospective, active hemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen‐UVA photochemical treatment
  publication-title: Vox Sang
– volume: 50
  start-page: 776
  year: 2010
  end-page: 86
  article-title: Direct assessment of cytomegalovirus transfusion‐transmitted risks after universal leukoreduction
  publication-title: Transfusion
– volume: 337
  start-page: 1861
  year: 1997
  end-page: 9
  article-title: Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions
  publication-title: N Engl J Med
– volume: 58
  start-page: 1506
  year: 2018
  end-page: 15
  article-title: Amotosalen/UVA treatment inactivates T cells more effectively than the recommended gamma dose for prevention of transfusion‐associated graft‐versus‐host disease
  publication-title: Transfusion
– volume: 54
  start-page: 2924
  year: 2014
  end-page: 30
  article-title: Inactivation of dengue virus in plasma with amotosalen and ultraviolet A illumination
  publication-title: Transfusion
– volume: 42
  start-page: 556
  year: 2002
  end-page: 66
  article-title: A randomized controlled trial comparing the frequency of acute reactions to plasma‐removed platelets and pre‐storage WBC‐reduced platelets
  publication-title: Transfusion
– volume: 153
  start-page: 393
  year: 2011
  end-page: 401
  article-title: A multi‐centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion
  publication-title: Br J Haematol
– volume: 337
  start-page: 1870
  year: 1997
  end-page: 5
  article-title: The threshold for prophylactic platelet transfusions in adults with acute myelogenous leukemia
  publication-title: N Engl J Med
– volume: 142
  start-page: 348
  year: 2008
  end-page: 60
  article-title: Platelet transfusion refractoriness
  publication-title: Br J Haematol
– volume: 111
  start-page: 226
  year: 2016
  end-page: 34
  article-title: Investigation of bacterial inactivation in apheresis platelets with 24 or 30 hours between inoculation and inactivation
  publication-title: Vox Sang
– year: 2016
– volume: 51
  start-page: 622
  year: 2011
  end-page: 9
  article-title: Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3‐year period
  publication-title: Transfusion
– volume: 40
  start-page: 761
  year: 2000
  end-page: 70
  article-title: Assessment of donor T‐cell function in cellular blood components by the CD69 induction assay: effects of storage, gamma irradiation, and photochemical treatment
  publication-title: Transfusion
– volume: 112
  start-page: 249
  year: 2017
  end-page: 56
  article-title: Patient outcomes and amotosalen/UVA‐treated platelet utilization in massively transfused patients
  publication-title: Vox Sang
– volume: 101
  start-page: 4195
  year: 2003
  end-page: 200
  article-title: Transfusion‐transmitted cytomegalovirus infection after receipt of leukoreduced blood products
  publication-title: Blood
– volume: 55
  start-page: 2104
  year: 2015
  end-page: 12
  article-title: Evaluation of the effectiveness of a pathogen inactivation technology against clinically relevant transfusion‐transmitted bacterial strains
  publication-title: Transfusion
– volume: 47
  start-page: 1972
  year: 2007
  end-page: 83
  article-title: High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion
  publication-title: Transfusion
– volume: 53
  start-page: 2375
  issue: 10 Pt 2
  year: 2013
  end-page: 83
  article-title: AAABB transfusion‐transmitted diseases emerging infectious diseases subgroup. transfusion‐transmitted emerging infectious diseases: 30 years of challenges and progress
  publication-title: Transfusion
– volume: 37
  start-page: 92s
  year: 1997
  article-title: Loss of inducible CD69 expression on donor T cells (CD3CD69) in platelet concentrates(PCs) by storage, irradiation, and photochemical treatment
  publication-title: Transfusion
– volume: 101
  start-page: 2426
  year: 2003
  end-page: 33
  article-title: Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial
  publication-title: Blood
– volume: 362
  start-page: 600
  year: 2010
  end-page: 13
  article-title: Dose of prophylactic platelet transfusions and prevention of hemorrhage
  publication-title: N Engl J Med
– volume: 44
  start-page: 1159
  year: 2004
  end-page: 65
  article-title: Photochemical treatment of platelet concentrates with amotosalen hydrochloride and ultraviolet A light inactivates free and latent cytomegalovirus in a murine transfusion model
  publication-title: Transfusion
– volume: 4
  start-page: 3
  year: 2010
  end-page: 8
  article-title: Leukoreduced blood components: advantages and strategies for its implementation in developing countries
  publication-title: Asian J Transfus Sci
– volume: 86
  start-page: 3598
  year: 1995
  end-page: 603
  article-title: A comparison of filtered leukocyte‐reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion‐associated CMV infection after marrow transplant
  publication-title: Blood
– volume: 368
  start-page: 1771
  year: 2013
  end-page: 80
  article-title: A no‐prophylaxis platelet‐transfusion strategy for hematologic cancers
  publication-title: N Engl J Med
– volume: 56
  start-page: S29
  issue: Suppl 1
  year: 2016
  end-page: 38
  article-title: The role of hemovigilance and postmarketing studies when introducing innovation into transfusion medicine practice: the amotosalen‐ultraviolet A pathogen reduction treatment model
  publication-title: Transfusion
– volume: 127
  start-page: 496
  year: 2016
  end-page: 502
  article-title: Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance
  publication-title: Blood
– volume: 171
  start-page: 6023
  year: 2003
  end-page: 31
  article-title: Allogeneic T cells treated with amotosalen prevent lethal cytomegalovirus disease without producing graft‐versus‐host‐disease following bone marrow transplantation
  publication-title: J Immunol
– volume: 38
  start-page: 839
  year: 1998
  end-page: 47
  article-title: Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation‐a prospective analysis
  publication-title: Transfusion
– volume: 103
  start-page: 333
  year: 2004
  end-page: 9
  article-title: Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness
  publication-title: Blood
– volume: 112
  start-page: 47
  year: 2016
  end-page: 55
  article-title: Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre
  publication-title: Vox Sang
– volume: 33
  start-page: 1
  year: 2004
  end-page: 7
  article-title: Novel processes for inactivation of leukocytes to prevent transfusion‐associated graft‐versus‐host disease
  publication-title: Bone Marrow Transplant
– volume: 52
  start-page: 1657
  year: 2012
  end-page: 66
  article-title: Dengue viremia in blood donors identified by RNA and detection of dengue transfusion transmission during the 2007 dengue outbreak in Puerto Rico
  publication-title: Transfusion
– volume: 104
  start-page: 1534
  year: 2004
  end-page: 41
  article-title: Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial
  publication-title: Blood
– volume: 370
  start-page: 427
  year: 2007
  end-page: 38
  article-title: Platelet transfusions
  publication-title: Lancet
– volume: 79
  start-page: 246
  year: 1991
  end-page: 50
  article-title: Use of leukocyte‐depleted patelets and cytomegalovirus seronegative red cells for prevention of primary cytomegalovirus infection after marrow transplant
  publication-title: Blood
– start-page: 2300
  year: 2000
  end-page: 10
– volume: 45
  start-page: 1864
  year: 2005
  end-page: 75
  article-title: Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial
  publication-title: Transfusion
– volume: 77
  start-page: 1
  year: 1999
  end-page: 5
  article-title: Reduction of platelet transfusion‐ associated sepsis by short‐term bacterial culture
  publication-title: Vox Sang
– year: 2015
– volume: 83
  start-page: 1683
  year: 1994
  end-page: 9
  article-title: Effect of gamma irradiation on T‐cell inactivation as assessed by limiting dilution analysis: implications for preventing transfusion associated graft vs. host disease
  publication-title: Blood
– ident: e_1_2_8_12_1
  doi: 10.1111/trf.12371
– volume: 79
  start-page: 246
  year: 1991
  ident: e_1_2_8_5_1
  article-title: Use of leukocyte‐depleted patelets and cytomegalovirus seronegative red cells for prevention of primary cytomegalovirus infection after marrow transplant
  publication-title: Blood
  doi: 10.1182/blood.V78.1.246.246
  contributor:
    fullname: Bowden RA
– ident: e_1_2_8_40_1
  doi: 10.1111/trf.13478
– ident: e_1_2_8_26_1
  doi: 10.1046/j.1537-2995.1999.39399219279.x
– ident: e_1_2_8_28_1
  doi: 10.1111/trf.14589
– ident: e_1_2_8_16_1
  doi: 10.1111/j.1537-2995.2010.02873.x
– ident: e_1_2_8_3_1
  doi: 10.1056/NEJMoa0904084
– ident: e_1_2_8_2_1
  doi: 10.1056/NEJM199712253372602
– ident: e_1_2_8_13_1
  doi: 10.1111/j.1537-2995.2012.03566.x
– ident: e_1_2_8_22_1
  doi: 10.1111/trf.12713
– ident: e_1_2_8_35_1
  doi: 10.1111/j.1365-2141.2008.07189.x
– ident: e_1_2_8_36_1
  doi: 10.1182/blood-2003-03-0940
– ident: e_1_2_8_39_1
  doi: 10.1182/blood-2002-10-3143
– ident: e_1_2_8_30_1
  doi: 10.1046/j.1423-0410.1999.7710001.x
– ident: e_1_2_8_34_1
  doi: 10.1046/j.1537-2995.1998.38998409004.x
– volume-title: INTERCEPT Blood System for Platelets
  year: 2015
  ident: e_1_2_8_20_1
  contributor:
    fullname: Cerus Corporation
– ident: e_1_2_8_49_1
  doi: 10.1111/trf.13171
– ident: e_1_2_8_47_1
  doi: 10.1038/sj.bmt.1704284
– ident: e_1_2_8_6_1
  doi: 10.1056/NEJM199712253372601
– ident: e_1_2_8_42_1
  doi: 10.1016/S0140-6736(07)61198-2
– ident: e_1_2_8_23_1
– start-page: 2300
  volume-title: Hematology: Basic Principles and Practice
  year: 2000
  ident: e_1_2_8_7_1
  contributor:
    fullname: Snyder E
– ident: e_1_2_8_11_1
  doi: 10.1182/blood-2015-07-655944
– ident: e_1_2_8_31_1
  doi: 10.1182/blood-2002-03-0932
– ident: e_1_2_8_10_1
  doi: 10.1182/blood-2015-01-620872
– ident: e_1_2_8_8_1
  doi: 10.1111/j.1537-2995.2009.02486.x
– ident: e_1_2_8_14_1
  doi: 10.1111/trf.13673
– volume: 37
  start-page: 92s
  year: 1997
  ident: e_1_2_8_25_1
  article-title: Loss of inducible CD69 expression on donor T cells (CD3CD69) in platelet concentrates(PCs) by storage, irradiation, and photochemical treatment
  publication-title: Transfusion
  contributor:
    fullname: Fiebig E
– ident: e_1_2_8_45_1
  doi: 10.1046/j.1537-2995.2000.40070761.x
– ident: e_1_2_8_29_1
  doi: 10.4103/0973-6247.59384
– ident: e_1_2_8_43_1
  doi: 10.1016/S0037-1963(01)90121-0
– ident: e_1_2_8_33_1
  doi: 10.1111/j.1365-2141.2011.08635.x
– ident: e_1_2_8_46_1
  doi: 10.1182/blood-2003-12-4443
– ident: e_1_2_8_17_1
  doi: 10.1111/vox.12489
– ident: e_1_2_8_21_1
– ident: e_1_2_8_37_1
  doi: 10.1046/j.1537-2995.2002.00094.x
– ident: e_1_2_8_4_1
  doi: 10.1056/NEJMoa1212772
– ident: e_1_2_8_50_1
  doi: 10.1111/vox.12410
– volume: 83
  start-page: 1683
  year: 1994
  ident: e_1_2_8_41_1
  article-title: Effect of gamma irradiation on T‐cell inactivation as assessed by limiting dilution analysis: implications for preventing transfusion associated graft vs. host disease
  publication-title: Blood
  doi: 10.1182/blood.V83.6.1683.1683
  contributor:
    fullname: Pelszynski MM
– ident: e_1_2_8_32_1
  doi: 10.1111/j.1537-2995.2005.00639.x
– ident: e_1_2_8_48_1
  doi: 10.1111/vox.12456
– ident: e_1_2_8_24_1
  doi: 10.1111/j.1537-2995.2004.03351.x
– volume-title: Haemovigilance Annual Report 2015
  year: 2016
  ident: e_1_2_8_44_1
  contributor:
    fullname: Amsler L
– ident: e_1_2_8_9_1
  doi: 10.1111/j.1537-2995.2007.01420.x
– ident: e_1_2_8_15_1
  doi: 10.1111/j.1537-2995.2009.02151.x
– ident: e_1_2_8_18_1
  doi: 10.1111/vox.12287
– ident: e_1_2_8_38_1
  doi: 10.1182/blood.V86.9.3598.bloodjournal8693598
– ident: e_1_2_8_27_1
  doi: 10.4049/jimmunol.171.11.6023
– ident: e_1_2_8_19_1
  doi: 10.1111/trf.13530
SSID ssj0002901
Score 2.387549
Snippet BACKGROUND Leukoreduction (LR) of platelet concentrate (PC) has evolved as the standard to mitigate risks of alloimmunization, clinical refractoriness, acute...
Leukoreduction (LR) of platelet concentrate (PC) has evolved as the standard to mitigate risks of alloimmunization, clinical refractoriness, acute transfusion...
BACKGROUNDLeukoreduction (LR) of platelet concentrate (PC) has evolved as the standard to mitigate risks of alloimmunization, clinical refractoriness, acute...
SourceID pubmedcentral
proquest
crossref
pubmed
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 1953
SubjectTerms Adult
Antisepsis - methods
Bacteria
Blood Platelets - cytology
Blood-Borne Pathogens - isolation & purification
Case-Control Studies
Cohort Studies
Complications
Cytomegalovirus
Disinfection - methods
Female
Furocoumarins
Gamma irradiation
Gamma Rays
Graft vs Host Disease - epidemiology
Graft vs Host Disease - etiology
Graft-versus-host reaction
Health risks
Hematopoietic stem cells
Humans
Infections
Infectious diseases
Irradiation
Isoimmunization
Leukocyte Count
Leukocytes - cytology
Male
Middle Aged
Mortality
Pathogens
Patients
Platelet Transfusion - adverse effects
Platelet Transfusion - methods
Platelet Transfusion - standards
Platelets
Screening
Stem cell transplantation
Stem cells
Thermal resistance
Transfusion
Transfusion Medicine
Transfusion Reaction - blood
Transfusion Reaction - epidemiology
Transfusion Reaction - prevention & control
Ultraviolet Rays
Virus Inactivation - drug effects
Virus Inactivation - radiation effects
Title Transfusion of pathogen‐reduced platelet components without leukoreduction
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Ftrf.15269
https://www.ncbi.nlm.nih.gov/pubmed/30919465
https://www.proquest.com/docview/2234294833
https://search.proquest.com/docview/2199195835
https://pubmed.ncbi.nlm.nih.gov/PMC6850058
Volume 59
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LS8NAEB5qBfEivo1WieLBSyDNbrZZPIlaiqhIqeAtbLIbFEsitbn7E_yN_hJnNg8sIngJgZ2QMI-db3YmMwCnGRqYUhiWIJiPPK6Y9BCFBB75As0GOq2aPd_di9Ejv3kKnzpw3vwLU_WHaA_cyDLsfk0GrpL3H0Y-n2U0vEfIJVhGWBORSgf8od2GKUFYpZf7Ho1Tr9sKURlP--iiM_qFMH8XSv4EsNYDDddhrYaO7kUl6w3omHwTVu7q5PgW3Fq_k5V0_uUWmUvDhgvUj6-Pzxk1aDXafZsitERJuVRJXuRUROHSSWxRzt2pKV8LS0iy2obH4fXkcuTVwxK8lCOo8EITcO0LmQQRgox-GmiGwZ9JMmmyZEB91kMd9bkOTZoJnzGNG5sWQkuTKp6hYe9AN8cX74GbSrTMSNAAspTiO4S0KVOhr6IkYVz5Dpw0XIvfqp4YcRNLIGtjy1oHeg0_49os3mPEIuj_eMSYA8ftMio0ZSlUbooSaagYS4aIDB3YrdjfvoUhupFc4MpgQTAtATXLXlzJX55t02wRhTRC0YEzK8K_PzyejIf2Zv__pAewikBKViVkPejOZ6U5RLAyT46sUuL1ahx8AznK6Ak
link.rule.ids 230,315,786,790,891,1382,11589,27955,27956,46085,46327,46509,46751
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NSsNAEB5qBfUi_hutGsWDl0Da3aRZ8CJiqdoWkRZ6C0l2g2JJSm3uPoLP6JM4s_mhpQjeArthw8zOzjezk28ArmM0sCDAsATBvGfxgAkLUUjLIl8gWVtGOdlzf-B2R_xp7IxrcFv-C5PzQ1QJN7IMfV6TgVNCesHK57OYuve4Yg3WORHBEa8zf6nOYbohzO-Xmxb1Uy94haiOp3p12RutQMzVSslFBKtdUGcHtgvsaN7lyt6Fmkr2YKNf3I7vQ087njijBJiZxiZ1G05xg_x8fc-IoVVJczpBbImqMqmUPE2oisKkVGyazc2Jyj5SPZGUdQCjzsPwvmsV3RKsiCOqsBzV4tJ2RdjyEGU0o5ZkGP2pMBYqDttEtO5Ir8mlo6LYtRmTeLJJ15VCRQGP0bIPoZ7gwsdgRgJN03OpA1lEAR5i2ogFjh14Ych4YBtwVUrNn-akGH4ZTKBofS1aAxqlPP3CLj59BCPoALnHmAGX1TDuaLqmCBKVZjiHqrGEg9DQgKNc_NUqDOGNQGUb0F5STDWB2LKXR5L3N82a7XoO9VA04Ear8O8P94evHf1w8v-pF7DZHfZ7fu9x8HwKW4iqRF5P1oD6fJapM0Qu8_Bcb9BfPMDqiA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB7xkBCXQguUtFBSxIFL0G7seGNxQsAKWkAIgcShUpT4oSJQstoml574CfxGfklnnAcsqBLiFsmO7HhmPN_Yk28AtiwaWJpiWIJgPg54ymSAKCQMyBdoNtCqJns-PRNHV_zHdXQ9BbvtvzA1P0R34EaW4fZrMvCRts-MvBxbKt4j5DTMcsFCirwOLp64o-iCsL5e7gdUTr2hFaI0nu7VSWf0CmG-TpR8DmCdBxouwK927nXiye1OVWY76u8LWsd3ftwifGiQqb9Xq9JHmDL5J5g7be7el-DEuTVb0fGaX1ifahkXqH6P9w9j4n812h_dIXJFRfApUb3IKUfDp4Peoir9O1PdFq4jqcIyXA0PL_ePgqYWQ6A4YpYgMiHXPSGzMEYM01ehZhhbmsxKY7MB0bhHOu5zHRllRY8xjfumFkJLo1Jucd9YgZkcB14FX0k0_FhQfTNF4SMiZsXSqJfGWcZ42vNgsxVKMqopN5I2VMF1Sdy6eLDWiitprO5PglAH3SuPGfPge9eM9kKXIGluigr7UK6XjBB4evC5lm43CkPwJLnAlsGE3LsOxMU92ZLf_Hac3CKOqEKjB9tOrP-feHJ5MXQPX97edQPmzg-Gycnx2c-vMI-QTdbJamswU44rs46wqMy-OfX_Bw4ACg4
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Transfusion+of+pathogen%E2%80%90reduced+platelet+components+without+leukoreduction&rft.jtitle=Transfusion+%28Philadelphia%2C+Pa.%29&rft.au=Sim%2C+Joycelyn&rft.au=Tsoi%2C+Wai+Chiu&rft.au=Lee%2C+Cheuk+Kwong&rft.au=Leung%2C+Rock&rft.date=2019-06-01&rft.issn=0041-1132&rft.eissn=1537-2995&rft.volume=59&rft.issue=6&rft.spage=1953&rft.epage=1961&rft_id=info:doi/10.1111%2Ftrf.15269&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_trf_15269
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0041-1132&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0041-1132&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0041-1132&client=summon